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Abstract
Background: Invasive micropapillary carcinoma of the breast (IMPC) is a histological tumor variant that occurs
with low frequency characterized by an inside-out formation of tumor clusters with a pseudopapillary arrangement.
IMPC is an aggressive tumor with poor clinical outcome. In addition, this histological subtype usually expresses
human epidermal growth factor receptor 2 (HER2) which also correlates with a more aggressive tumor. In this
work we studied the clinical significance of IMPC in HER2-positive breast cancer patients treated with adjuvant
trastuzumab. We also analyzed mucin 4 (MUC4) expression as a novel biomarker to identify IMPC.
Methods: We retrospectively studied 86 HER2-positive breast cancer patients treated with trastuzumab and
chemotherapy in the adjuvant setting. We explored the association of the IMPC component with
clinicopathological parameters at diagnosis and its prognostic value. We compared MUC4 expression in IMPC
with respect to other histological breast cancer subtypes by immunohistochemistry.
Results: IMPC, either as a pure entity or associated with invasive ductal carcinoma (IDC), was present in 18.6%
of HER2-positive cases. It was positively correlated with estrogen receptor expression and tumor size and inversely
correlated with patient’s age. Disease-free survival was significantly lower in patients with IMPC (hazard ratio = 2.6;
95%, confidence interval 1.1–6.1, P = 0.0340). MUC4, a glycoprotein associated with metastasis, was strongly
expressed in all IMPC cases tested. IMPC appeared as the histological breast cancer subtype with the highest
MUC4 expression compared to IDC, lobular and mucinous carcinoma.
Conclusion: In HER2-positive breast cancer, the presence of IMPC should be carefully examined. As it is often not
informed, because it is relatively difficult to identify or altogether overlooked, we propose MUC4 expression as a
useful biomarker to highlight IMPC presence. Patients with MUC4-positive tumors with IMPC component should
be more frequently monitored and/or receive additional therapies.
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Background
Invasive micropapillary carcinoma of the breast (IMPC)
is defined as a low-frequent tumor variant of invasive
carcinomas characterized by a unique inside-out forma-
tion of tumor clusters with a pseudopapillary arrange-
ment that is present in ~6% of all breast cancers [1, 2].
These clusters are separated from each other by a clear
space defined by the intervening stroma. IMPC was
originally described as a histological subtype in 1980 by
Fisher et al. [3], and was listed for the first time in 2003
as a histological subtype of invasive breast carcinoma in
the World Health Organization (WHO) classification of
breast tumors [4]. IMPC has an angioinvasive pheno-
type that allows its spread into blood vessels, which
leads to higher rates of lymph node metastasis and poor
clinical outcome [5, 6]. In addition, this histological en-
tity is more likely to present human epidermal growth
factor receptor-2 (HER2) and estrogen receptor (ER)
expression [5, 7, 8]. Although IMPC constitutes a histo-
logical breast cancer subtype per se, its occurrence is
most commonly associated with invasive ductal carcin-
oma (IDC) in which the micropapillary component is
variable (mixed IMPC). Interestingly, pure IMPC har-
bors patterns of genomic aberrations and phenotype
similar to those found in mixed IMPC [9]. In line with
this evidence, it has been reported that the incidence of
lymph node dissemination is independent of the rela-
tive amount of micropapillary features in the tumor.
Once the micropapillary component is present in any
amount, the behavior and outcome of the disease in pa-
tients with mixed IMPC are similar to those bearing
pure IMPC tumors [1, 6]. In spite of this, pathologists
frequently underreport this histological entity, because
it is relatively difficult to identify or altogether over-
looked. Therefore, it is vital to report IMPC presence,
even when found in subtle proportions. A sensitive bio-
marker thus become instrumental in revealing its
presence.
HER2-positive breast cancers are characterized by
their aggressive behavior [10]. The treatment of choice
is the administration of the monoclonal antibody tras-
tuzumab associated with chemotherapy [11]. However,
up to 42% of patients treated with neoadjuvant trastu-
zumab, and 27% of patients treated with adjuvant
trastuzumab, experience disease progression [12, 13].
We have recently demonstrated that mucin 4 (MUC4) ex-
pression in HER2-positive breast cancer is a biomarker of
poor prognosis in patients treated with trastuzumab in the
adjuvant setting [14]. MUC4, a membrane glycoprotein,
promotes metastasis given its ability to confer anti-
adhesive properties to breast cancer cells [15]. In particu-
lar, we have proved that tumor necrosis factor alpha
(TNFα) drives MUC4 expression in HER2-positive breast
cancer through the activation of NF-kB transcription
factor. We demonstrated that MUC4 induced by TNFα is
able to shield trastuzumab epitope on the HER2 molecule
and constitutes a mechanism by which TNFα promotes
trastuzumab resistance in HER2-positive cancers [14].
Interestingly, TNFα presence has been associated with
microvessel density in IMPC [16]. Since pathologists’
examination of our HER2-positive cohort revealed several
IMPC cases, and because MUC4 and IMPC share several
characteristics [15, 16], we wanted to explore whether
MUC4 expression could be a feature of this breast cancer
subtype.
To our knowledge, the IMPC data published so far
focused on comparing this histological breast cancer
subtype with others. Here, we present a study of IMPC
incidence in HER2-positive breast cancer patients and
its potential clinical significance on responsiveness
benefit to adjuvant trastuzumab and chemotherapy. We
also evaluated whether the expression of MUC4 by IHC




Breast cancer paraffin-embedded tissue sections of 86
consecutive patients with HER2-postive primary breast
cancer were retrieved from the Pathology Department
of Hospital Juan A. Fernández, Instituto de Oncología
Henry Moore, (Buenos Aires, Argentina) and Hospital
de Temuco, (Temuco, Chile) from 2005 to 2014. The
median follow-up time was 30 months (range 0.5–
9 years). Also, a cohort of 113 consecutive breast can-
cer samples from Instituto de Oncología Henry Moore
was included in the analysis as a control. This study
was conducted under the provisions of the Declaration
of Helsinki and informed written consents were ob-
tained from all patients before inclusion. Study proto-
cols were approved by the Ethic Committees of the
participating institutions. Patients were included if they
had received adjuvant trastuzumab and chemotherapy
treatment, had complete data on baseline clinical fea-
tures and treatment outcomes, and were preoperatively
chemotherapy and radiotherapy naïve. Patients received
standard adjuvant chemotherapy plus 1 year of treat-
ment with trastuzumab: 4 cycles, one every three
weeks, of doxorubicin (60 mg/m2 i.v.) plus cyclophos-
phamide (600 mg/m2 i.v.) followed by 4 cycles every
3 weeks of paclitaxel (80 mg/m2 i.v.), plus trastuzumab
(8 mg/kg i.v. loading dose with first dose of docetaxel
followed by 6 mg/kg every 3 weeks for 1 year). Pre-
treatment patient staging was classified according to
the American Joint Committee on Cancer (AJCC)
system through the Elston and Ellis histological grading
system. Tumor specimens were anonymized for this
study.
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Histopathological analysis and immunohistochemistry
(IHC)
For IHC, antigen retrieval was performed in 5 μm par-
affin embedded tissue sections in positively charged
slides in 10 mmol/L sodium citrate buffer pH 6 for
50 min at 92 °C. Slides were incubated with antibodies
against MUC4 (1:50, 1G8 Santa Cruz Biotechnology,
Santa Cruz, CA, 1:50) or TNFα (#9739, 1:100, Abcam,
Cambridge, United Kingdom) overnight at 4 °C.
Sections were then incubated with a biotinilated anti-
mouse or biotinilated anti-rabbit secondary antibody,
dilution 1:400, for 30 min and then with incubated with
the VECTASTAIN® Elite® ABC-HRP Kit (Vector,
Burlingame, CA) and developed with DAB (3,3′-diami-
nobenzidine) (Cell Marque, Rocklin, CA). MUC4 quan-
tification was done using a score of 0 to 3+, as
previously reported by Workman et al. [17]. TNFα
quantification was done as we previously reported [14].
The scoring system was the following: score: 0, no stain
to less than 30% of cells staining faintly; 1+, over 30%
of cells staining light to moderate; 2+, over 50% of cells
staining moderately; 3+, intense staining of majority of
the epithelial population [14]. Immunostainings were
run with known positive and negative tissue controls.
Expression and localization of the proteins were inde-
pendently evaluated by three pathologists, GI, IF and
MA, who were masked to clinical data and treatment
outcome. Score discrepancies were re-evaluated and
reconciled on a multiple-headed microscope. Tumors
were considered MUC4-positive or TNFα positive when
they exhibited a score of 2+ or 3+ [14]. HER2 was evalu-
ated by IHC with the polyclonal antibody A0485 (Dako)
and was scored according to the American Society of
Clinical Oncology/College of American Pathologists
guidelines (ASCO/CAP). Tumors were considered HER2-
positive if they presented a score of 3+ by IHC or score 2+
and confirmed HER2 amplification by FISH (PathVysion™,
Vysis Inc., Downers Grove, IL). The immunohistochemi-
cal assessment of ER and PR receptors was made using
the 6F11 (Novocastra Laboratories, U.K) and 1A6h PRa2
+ hPRa3 (NeoMarkers, Freemont, CA) antibodies, re-
spectively, and were scored as described previously [18].
Guidelines for Reporting Recommendations for Tumor
Marker Prognostic Studies (REMARK) were followed in
this work [19].
MUC4 validation cohort
In order to evaluate MUC4 in an independent patient
cohort, we used gene expression data from 113 patients.
Data is available from ArrayExpress® repository under
accession number “E-NCMF-3”. The data set was evalu-
ated and processed (quantile normalized) by means of
the lmdme [20] and the limma [21] libraries from Bio-
conductor® repository and run into the R environment
[22]. Differential gene expression was analyzed through
the “eBayes” function from limma. The script code is
available in the Additional file 1.
Statistical analysis
Analyses were performed using SPSS software version
15.0 (SPSS Inc.; Chicago, IL). Correlations between
categorical variables were performed using the χ2-test or
Fisher’s exact test when the number of observations
obtained for analysis was under five. Disease-free
survival (DFS) was calculated from the date of initial
diagnosis to the date of recurrence or death, whichever
came first. Cumulative DFS probabilities were calculated
according to the Kaplan-Meier method and statistical
significance was analyzed by log-rank test or Wilcoxon
test. For univariate analysis, we used the Cox propor-
tional hazards regression model. The hazard ratio (HR)
and its 95% confidence interval (CI) were calculated for
each variable. Statistical differences of MUC4 expres-
sion were determined by Kruskal-Wallis test and
Dunn’s test using GraphPad Prism 6 software (GraphPad
Software, La Jolla, CA, USA). P values under 0.05
were considered statistically significant and all re-
ported P values were 2-sided.
Results
IMPC is associated with poor outcome in HER2-positive
breast cancer patients
As HER-2 expression is frequently observed in IMPC
[8], our purpose was to study the incidence and clinical
relevance of this histological breast cancer subtype in
HER-2 positive breast cancer patients. We have a cohort
of 86 HER2-positive breast cancer patients, treated with
trastuzumab and chemotherapy (see details in Methods)
in the adjuvant setting, whose clinicopathological fea-
tures are shown in Table 1. We found that 16 tumors
(18.6% of the HER-2-positive tumors) were either pure
(6 cases) or had different proportions of IMPC compo-
nent mixed with IDC (IMPC 10–30%:4 cases; 31–70%: 2
cases; 71–90%: 4 cases). In accordance with previous re-
ports [23], we observed that IMPC presence (pure and
mixed cases) was associated with younger patients, lar-
ger tumor size and positive ER expression, which we
considered hormone receptor (HR) positive (Table 2).
We observed a trend of association between IMPC and
lymph node status (Table 2). Interestingly, univariate
analysis showed that IMPC was associated with poor
DFS (HR = 2.6; 95% CI 1.1–6.1; P = 0.0340) (Fig. 1a).
Also, lymph node metastasis (HR = 3.8; 95%, CI: 1.4–
10.5; P = 0.0083) and clinical stage status (HR = 4.7;
95%CI 2.0–11.0; P = 0.00004) was associated with re-
duced DFS (Fig. 1a). Kaplan-Meier analysis revealed that
IMPC presence was associated with reduced DFS in pa-
tients treated with standard trastuzumab treatment in
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the adjuvant setting (log rank P = 0.028; Fig. 1b). No
differences were observed in DFS between patients with
pure (n = 6) and mixed IMPC (n = 10, P = 0.594, data not
shown). Our results show that the presence of IMPC, ei-
ther as a pure or mixed entity, reveals a subgroup of
HER2-positive breast cancer patients with poor outcome
to adjuvant trastuzumab and chemotherapy.
MUC4 is overexpressed in IMPC
We already demonstrated that MUC4 expression is a bio-
marker of resistance to adjuvant trastuzumab treatment
[14]. As we found that 18.6% of the HER2-positive cohort
analyzed had IMPC differentiation (pure or mixed) and
showed poor outcome to trastuzumab and chemotherapy,
we explored whether MUC4 is expressed in IMPC cases.
MUC4 detection by IHC showed strong cytoplasmic
staining in all IMPC tested (Table 3, P = 0.0003). This was
also true for 20 additional cases of IMPC, whose follow-
up data was not available, and was not included in this
study. MUC4 positivity was observed in IMPC located in
nodal metastasis and in primary tumors, independently of
the percentage of IMPC present in the sample (Fig. 2a).
As we observed that a subgroup of MUC4-positive tu-
mors had IMPC differentiation, we compared the DFS of
patients whose tumors were MUC4-negative, MUC4-
positive without IMPC and MUC4-positive with IMPC
component. Figure 2b shows that MUC4-negative patients
benefit more from trastuzumab than MUC4-positive pa-
tients (either with or without IMPC). However, MUC4-
positive patients with IMPC tumors tended to have lower
DFS after 3 years of the onset of treatment than the ones
having MUC4-positive tumors without IMPC. In addition,
patients with tumors MUC4-positive and IMPC (pure or
mixed) were younger than patients with MUC4-positive
without IMPC and MUC4-negative tumors (Table 4).
To compare MUC4 expression in IMPC with respect to
other histological breast cancer subtypes, we performed
IHC staining on an independent cohort of 113 breast
cancer samples used as control. Their baseline clinico-
pathological data is shown in Additional file 2: Table S1.
Histological analysis of this cohort showed that 79.6%
were IDC, 9,8% infiltrating lobular carcinoma (ILC), 5.3%
mucinous carcinoma and 5.3% IMPC (Additional file 3:
Table S2).We observed that IMPC is the histological
entity with the highest MUC4 expression (Fig. 2c and d).
Contrastingly, infiltrating lobular carcinoma (ILC)
and mucinous carcinoma expressed MUC4 faintly, while
IDC exhibited intermediate expression levels (Fig. 2c and
d). Concordantly, in our cohort of 86 HER2-positive
Table 1 Clinicopathological characteristics of the HER2+ cohort
Characteristic N° patients % Median Range
Total number of patients 86
Age (years) 50 25–79
























Estrogen receptor positive 66.3
Progesterone receptor positive 55.8
Table 2 Association between IMPC and clinicopathological
characteristics
Clinicopathological characteristics non-IMPC IMPC P
n (%) n (%)
Menopausal status pre 35 (50.0) 13 (81.3) 0.021
post 35 (50.0) 3 (18.8)
Tumor size 1 31 (44.9) 2 (12.5) 0.014
2–4 38 (55.1) 14 (87.5)
Lymph node status 0 39 (55.7) 5 (31.3) 0.068
1–3 31 (44.3) 11 (68.7)
Clinical stage I, II 52 (74.3) 13 (81.3) 0.41
III 18 (25.7) 3 (18.7)
Histological grade 1,2 30 (46.2) 5 (35.7) 0.447
3 35 (53.8) 9 (64.3)
Estrogen receptor Negative 27 (38.6) 2 (12.5) 0.04
Positive 43 (61.4) 14 (87.5)
Progesterone receptor Negative 33 (47.1) 5 (31.3) 0.248
Positive 37 (52.9) 11 (68.7)
The numbers in italic correspond to statistically significant p values
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patients, MUC4 score in IMPC was higher than in IDC
(Fig. 2e).
To validate our findings, data from Lopez-Garcia et al.
[24] was used to contrast the gene expression of MUC4
mRNA (ENST00000314335) levels among IMPC, IDC,
ILC and mucinous carcinoma using linear models of
microarray data (Limma) [21]. In spite of the small num-
ber of cases reported in this study (IMPC, n = 8, IDC, n
= 10, ILC, n = 20; mucinous carcinoma, n = 10), the data
showed a statistically significant increase in mRNA
MUC4 levels in IMPC with respect to those in mucinous
carcinoma (Fig. 2f, P = 0.0164). mRNA MUC4 levels in
IMPC did not show significant differences between IDC
and ILC in this data set. Interestingly, the differences of
MUC4 protein expression in IDC and ILC were not seen
at mRNA level. All these results proved that MUC4 is
overexpressed in IMPC and that it is a sensitive bio-
marker useful to show IMPC presence.
Discussion
Here we found that 18.6% of HER-2 positive breast can-
cers have IMPC differentiation (pure or mixed entities) in
contrast to the 6% reported in breast cancer in general sta-
tistics [1, 2]. This characteristic was more strongly associ-
ated with HER-2 positive/HR positive tumors (14/57,
24.6%) than with HER2-positve/HR-negative breast cancer
subtype (2/29, 6.9%). To our knowledge, this is the first
study in which IMPC incidence is explored in a HER2
positive cohort. It has been described that between 30 and
80% of IMPC are HER2-positive [7, 8]. However, the im-
pact of IMPC on trastuzumab efficacy has not been ex-
plored. Here, we revealed that IMPC is associated with
poor DFS of patients treated with adjuvant trastuzumab
and chemotherapy.
Interestingly, our results clearly show that MUC4 is
overexpressed in IMPC as compared to IDC, ILC and mu-
cinous carcinoma. Cytoplasmic staining of MUC4 is
strong in all the studied IMPC cases including those with
metastatic lesions and primary tumors, even when the
IMPC component is as small as 10%. These results based
on MUC4 protein expression by IHC were also confirmed
in silico, using mRNA from an independent cohort [24]
where a significant increase in MUC4 mRNA levels in
IMPC was found with respect to the mucinous carcinoma.
MUC4 mRNA levels could attained no statistical signifi-
cance when comparing IMPC with IDC or ILC.. Other
biomarkers have been used to characterize IMPC. For ex-
ample, mucin 1 (MUC1) is present at the reversed apical
membrane of IMPC clusters. However, MUC1 exhibits a
membrane pattern together with cytoplasmic staining in
the mixed IMPC, rendering the membrane staining only a
marker of the pure entity [25]. The epithelial membrane
antigen (EMA) also shows the “inside-out” staining in
IMPC, but IDCs with osteoclastic giant cells also have a
similar EMA staining pattern [26]. Recently, it was re-
ported that p120 immunostaining was useful to determine
the presence of IMPC [27]. In fact, p120 has the advantage
of showing membrane staining with a cleaner background
than that of EMA IHC, resulting in a better determination
of IMPC features. Our previous report demonstrated that
MUC4, induced by TNFɑ, shields the trastuzumab bind-
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Fig. 1 IMPC is associated with poor outcome to adjuvant trastuzumab treatment in HER2-positive breast cancer patients. a Forest plot showing
the hazard ratios (HR, squares) and 95% confidence intervals (CI, horizontal lines) of Cox univariate subgroup analysis. b Kaplan–Meier analysis of
the probability of DFS of patients who received adjuvant trastuzumab treatment, based on the presence of IMPC. Log rank test was used
Table 3 Association between MUC4 expression and IMPC
MUC4 non-IMPC IMPC P
n (%) n (%)
Negative 31 (44.3) 0 (0) 0.0003
Positive 39 (55.7) 16 (100)
The numbers in italic correspond to statistically significant p values
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dependent cell cytotoxicity is impaired [14]. In addition,
TNFα presence has been positively associated with micro-
vessel density (MVD) in IMPC [16]. We also observed
strong intensity of TNFα staining in all IMPC samples
(Additional file 4: Figure S1 data not shown). It would
be useful to have a biomarker panel to determine IMPC
by quantification of MVD, and VEGF, p120 and MUC4
staining by IHC. We also proved that MUC4
expression is associated with resistance to adjuvant tras-
tuzumab administration and chemotherapy in HER2-
positive breast cancer patients. Taken together, our results
Fig. 2 MUC4 is overexpressed in IMPC. a Representative images of H&E and MUC4 staining by IHC of pure, mixed and metastatic IMPC.
b Kaplan–Meier analysis of the probability of DFS of patients who received adjuvant trastuzumab treatment, based on the expression of MUC4
and IMPC. c Representative images of MUC4 staining of IMPC in different histological breast cancer subtypes by IHC. MUC4 expression was
scored according to Workman et al. [17]. d and e Scores of MUC4 expression classified in the histological subtypes IMPC, IDC, ILC and mucinous
carcinoma in a cohort of 113 invasive breast cancer samples and in the 86 HER2-positive breast cancer cohort respectively. f Log Fold Change
(FC) expression (Tumor vs. Universal reference) sample distribution for MUC4 over each breast cancer subtype. *P < 0.05, **P < 0.01
Table 4 Association of expression of MUC4 and IMPC with age
at diagnosis








< 50 13 (42.0) 22 (56.4) 13 (81.3) 0.036
≥50 18 (58.0) 17 (43.6) 3 (18.7)
The numbers in italic correspond to statistically significant p values
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show that, MUC4 presents itself as a sensitive biomarker
for IMPC detection. In addition, we postulate that the ex-
pression of MUC4 in IMPC could be one of the causes of
the aggressive behavior of this tumor.
Several reports have acknowledged that IMPC is associ-
ated with worse prognosis [28, 29]. In line with this evi-
dence, our work showed that IMPC in HER2-positive
breast cancer is associated with ER expression, younger
patients and poor benefit to standard adjuvant trastuzu-
mab and chemotherapy. In conclusion, our findings
strongly recommend seeking out the IMPC component,
and informing its presence, even if the IMPC component
is subtle, particularly in the case of HER2 positive/HR
positive breast cancer. We therefore suggest the introduc-
tion of MUC4 determination to help identify the IMPC
component. There are no specific treatments today for
IMPC, but pursuant to our findings, the oncologist should
subject patients to more frequent monitoring and other
HER2-targeted therapies (i.e.pertuzumab) and/or TNFα
blocking strategies.
Conclusion
In this work we have shown that MUC4 is overexpressed
in IMPC and, moreover, MUC4 staining by IHC is a useful
biomarker to define IMPC presence, a difficult task since
IMPC tends to be overlooked and there are no reliable
biomarkers available. We propose a panel of biomarkers
to determine the micropapillary histological subtype con-
sisting of MUC4, VEGF y p120. We also showed that
IMPC in HER2-positive breast cancer is associated with
ER expression, younger patients and poor benefit to
standard adjuvant trastuzumab and chemotherapy. In
conclusion, our findings strongly recommend seeking and
informing IMPC presence, even if the micropapillary com-
ponent is subtle, particularly in the case of HER2 positive/
HR positive breast cancer. Since there are not specific
treatments available today for IMPC, the results exposed
in this work indicate that the oncologist should subject
patients to more frequent monitoring and other HER2-
targeted treatments (i.e pertuzumab) and/or TNFα block-
ing strategies to provide a better outcome for HER2
positive/HR positive IMPC breast cancer patients.
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